What changed today in Metabolic: 4 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
The signal
NPHLA tracked 4 new official records on this desk today: 4 trial updates.
Why this matters
GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.
What changed
- Trial status changed to “Recruiting”: MARITIME-T2D-3 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes)[1]
- New trial registered: REDEFINE (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High…)[2]
- New trial registered: A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)[3]
- New trial registered: Enith-MACE (A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease)[4]
Who this affects
- Weight-management clinics
- Med spas
- Pharmacists
- Prescribers
- Medical directors
- Practice owners & operators
What to watch next
No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.
NPHLA takeaway
These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.
Source file
- [1]
- [2]
- [3]
- [4]
Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.